supp.ai
Discover Supplement-Drug Interactions
Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago
Research Papers that Mention the Interaction
“Tolerability of the treatment with rifaximin was decidedly higher with respect to lactulose.”
Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.“Finally, a recent … the combination of rifaximin … lactulose improves clinical efficacy and reduces mortality in patients with hepatic encephalopathy.3 In this population-based cohort, we suggest further statistical … variables of lactulose and “lactulose plus rifaximin” in Table 2 and one variable of “lactulose plus rifaximin” in Table 3.”
“Addition of rifaximin to standard lactulose therapy may result in substantial reductions in healthcare resource utilization over the long term, by reducing overt HE recurrence and associated rehospitalization.”
“These studies showed that lactulose is effective for the prevention of overt HE recurrence over the long term and that the addition of rifaximin to lactulose significantly reduces the risk of overt HE recurrence and HE-related hospitalization, compared with lactulose therapy alone, without compromising tolerability.”
“This analysis estimated the cost effectiveness of rifaximin-α 550 mg twice daily plus lactulose versus lactulose alone in United Kingdom (UK) cirrhotic patients with OHE.”
“When added to lactulose, rifaximin reduces the risk of recurrent HE and readmission (4, 6, 7).”
“Continuous therapy with rifaximin in combination with lactulose significantly reduces the risk of overt HE, recurrence of HE and HE-related hospitalizations in randomized, double-blind, placebo-controlled clinical trials.”
“Second, patients treated with combined lactulose and rifaximin were excluded.”
“There was a significant decrease in mortality after treatment with lactulose plus rifaximin vs. lactulose and placebo (23.8% vs. 49.1%, P<0.05).”
“The combination of rifaximin and lactulose may be considered in the treatment of HE and in patients refractory to monotherapy.”
“The combination of rifaximin and lactulose should be considered for the prevention of HE, especially after the second episode of HE recurrence.”
“One study found that rifaximin produced a cost savings/patient/year of more than $3000 over lactulose therapy.”
Help us improve supp.ai, we'd love to hear your feedback: Submit Feedback